carbamazepine vs glecaprevir/pibrentasvir
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of carbamazepine and glecaprevir/pibrentasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7 DRUG INTERACTIONS Carbamazepine, efavirenz, and St. Coadministration of carbamazepine, efavirenz containing regimens, and St. Carbamazepine, phenytoin, efavirenz, and St.
Tegretol
Mavyret
Carbamazepine is a medicine used to control seizures and treat nerve pain. It works by reducing abnormal electrical activity in the brain and calming nerve signals.
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Carbamazepine is used to treat certain types of seizures, including partial seizures and generalized tonic-clonic seizures. It can also treat mixed seizure patterns. Carbamazepine also treats the pain from trigeminal neuralgia, a nerve disorder that causes intense facial pain. It is also sometimes used for glossopharyngeal neuralgia.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Carbamazepine is an anticonvulsant. It works by reducing the spread of seizure activity in the brain. It also stabilizes nerve impulses to reduce pain.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
- • Dizziness
- • Drowsiness
- • Unsteadiness
- • Nausea
- • Vomiting
- • Headache
- • Feeling tired
- • Nausea
- Seizure 3,609
- Drug Interaction 3,369
- Fall 3,044
- Dizziness 2,862
- Pyrexia 2,689
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
Carbamazepine can cause severe skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be fatal. If you are of Asian descent, you may need a blood test before starting this medicine. Carbamazepine can also cause serious blood problems like aplastic anemia and agranulocytosis. Contact your doctor right away if you develop a fever, sore throat, rash, or unusual bleeding or bruising.
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Carbamazepine may harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if carbamazepine passes into breast milk, so talk to your doctor about breastfeeding.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
Also Compare, Nearby Drugs
Compare carbamazepine with
How to Read This carbamazepine vs glecaprevir/pibrentasvir Comparison
carbamazepine is classified in the Anticonvulsant drug class, while glecaprevir/pibrentasvir sits within the NS3/4A/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, carbamazepine has 15,573 submissions while glecaprevir/pibrentasvir has 7,019. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to carbamazepine can speed up how your body breaks down the hepatitis c medicine, which may lower the amount of medicine in your blood. this could make the treatment less effective at fighting the virus.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for carbamazepine or glecaprevir/pibrentasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.